Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeomin in Restless Leg Syndrome
NCT01931878Phase 2Completed
- Sponsor
- Yale University
- Start
- Sep 2012
- Primary completion
- Aug 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of botulinum toxin type A in restless legs syndrome (RLS) (2 arms), sponsored by Yale University. Primary endpoint: Mean Total Restless Leg Syndrome Rating Scale Score at 6 weeks. Started Sep 2012; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on NCT01931878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01931878.